Resources

February 2024 | Poster
Activity of orotomide F901318 against clinical isolates of Scedosporiumspp. and Lomentosporaprolificans
February 2024 | Poster
Molecular Identification of Scedosporiumspecies from CF Patients and In Vitro Susceptibility of the Novel Antifungal Compound F901318
February 2024 | Poster
F901318, a Novel Antifungal Agent from the Orotomide Class: Discovery and Mechanism of Action
February 2024 | Poster
Pharmacokinetics of F901318 in man from an Intravenous Single Ascending Dose Study
February 2024 | Poster
Spectrum of Activity of F901318, the First Agent from the New Orotomide Class of Antifungals
February 2024 | Poster
Pharmacokinetics of the Novel Antifungal Agent F901318 in Mice, Rats and Cynomolgus Monkey
February 2024 | Poster
Activity of F901318, a Member of the New Orotomide Class of Antifungal Agents, against Clinical Aspergillus Isolates from the UK and Austria
February 2024 | Poster
In Vivo Efficacy of Orally Dosed F901318, in a Murine Model of Disseminated Aspergillosis
February 2024 | Poster
Pharmacokinetics and Pharmacodynamics (PK-PD) of F901318 Against Aspergillus Fumigatus
February 2024 | Poster
Activity of F901318 against azole-resistant and difficult-to-treat Aspergillus species
February 2024 | Poster
The Novel Orotomide F901318 Demonstrates Potent In vitro Antifungal Activity Against Lomentospora and Scedosporium Species
February 2024 | Poster
Assessment of the duration of infusion on the tolerability and repeat dose pharmacokinetics of F901318 in healthy volunteers
February 2024 | Poster
An Open Label Study in Healthy Volunteers to Evaluate the Potential for Cytochrome P450 3A4 Inhibition by F901318 using Oral Midazolam as a Probe
February 2024 | Poster
In Vitro Susceptibility Testing of the Novel Orotomide Antifungal Agent F901318 against Australian Scedosporium and Lomentospora Pathogens
February 2024 | Poster
Multiple Dose Pharmacokinetics of an Immediate-Release Tablet Formulation of F901318 in Healthy Male and Female Subjects
February 2024 | Poster
EUCAST Susceptibility Testing of F901318: MIC Data for Contemporary Clinical Mould Isolates
February 2024 | Poster
In vivo efficacy of olorofim against systemic infection caused by Scedosporium apiospermum, Pseudallescheria boydii and Lomentospora prolificans in neutropenic CD 1 mice
February 2024 | Poster
Olorofim EUCAST susceptibility testing of contemporary moulds: in vitro activity and improved reproducibility
February 2024 | Poster
Molecular mechanism and frequency of olorofim resistance in Aspergillus fumigatus
February 2024 | Poster
In vitro susceptibility of olorofim against 1,682 clinical Aspergillus isolates
February 2024 | Poster
The effect of the orotomide antifungal olorofim on the growth and viability of Scedosporium and Lomentospora species
February 2024 | Poster
Evaluation of the in vitro activity of olorofim against Fusarium Species
February 2024 | Poster
Olorofim is potent against M. mycetomatis – most common eumycetoma causative agent
February 2024 | Abstract
Molecular characterisation of Fusarium oxysporum species complex isolates from the United States and susceptibility profile of the investigational antifungal olorofim
Source: Abstract 5483
February 2024 | Abstract
Successful use of the novel antifungal olorofim in the treatment of disseminated coccioidomycosis
Source: Abstract 3203
February 2024 | Abstract
A case of Lomentospora prolificans (Lo Pro) treated with the novel antifungal olorofim
Source: Abstract 2585
February 2024 | Abstract
Antifungal susceptibility profiles of olorofim [formerly F901318), and currently available systemic antifungals against mould and yeast phases of Talaromyces marneffei
Source: Abstract 1358
February 2024 | Abstract
Olorofim for a case of severe disseminated Lomentospora prolificans infection
Source: Abstract 118
February 2024 | Presentation
F2G comments at FDA Antifungal workshop 4th August 2020
February 2024 | Presentation
F2G comments at FDA Valley Fever workshop 5th August 2020
February 2024 | Video
Biotech Showcase™ 2019: F2G accelerates Phase IIb program vs life-threatening fungal infections
Source: SOURCE: Biotech Showcase™
February 2024 | Video
BioPharma Day Presentation, NALS Conference November 2020
Scroll to Top